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Abstract
Purpose The prognosis of pancreatic cancer ranks among the
worst of all cancer types, which is primarily due to the fact that
during the past decades little progress has been made in its
diagnosis and treatment. Here, we set out to investigate the
role of microRNA 138 (miR-138-5p) in the regulation of
pancreatic cancer cell growth and to assess its role as putative
therapeutic target.
Methods qRT-PCR was used to examine the expression of
miR-138-5p in 8 pancreatic cancer cell lines and 18 primary
human pancreatic cancer samples. A lentivirual vector con-
taining miR-138-5p mimics (lv-miR-138-5p) was used to
exogenously over-express miR-138-5p in the pancreatic can-
cer cells lines Capan-2 and PANC-1. The effect of this over-
expression on cell proliferation was examined using an
in vitro propidium iodide fluorescence assay. Capan-2 cells
exogenously over-expressing miR-138-5p were transplanted
into nude mice to examine its in vivo effect on tumor growth.
A predicted target ofmiR-138-5p (FOXC1)was first validated
using a luciferase assay and, subsequently, down-regulated by
siRNA to assess its effect on pancreatic cancer cell growth.
Results We found that miR-138-5p was markedly down-
regulated in both pancreatic cancer cell lines and primary
human pancreatic cancer samples, compared to a human
pancreas ductal epithelial (HPDE) cell line and normal
pancreatic tissues, respectively (P<0.05). In addition, we
found that in the pancreatic cancer cells lines Capan-2 and
PANC-1 lentiviral transfection of miR-138-5p mimicked up-
regulation of the endogenous expression of miR-138-5p and,
concomitantly, inhibited cancer cell proliferation (P<0.05).
The exogenous over-expression of miR-138-5p also led to a
significant inhibition of tumor formation in vivo. Using a
luciferase assay, we found that miR-138-5p directly targets
FOXC1. In conformity with this notion, we found that
FOXC1 was down-regulated upon miR-138-5p over-
expression in pancreatic cancer cells. Finally, we found that
silencing of FOXC1 by siRNA had an inhibitory effect on
pancreatic cancer cell growth.
Conclusions Our data indicate that miR-138-5p may play an
important role in regulating pancreatic cancer cell growth,
possibly through targeting FOXC1. Over-expression of miR-
138-5p may serve as a novel approach for the treatment of
patients with pancreatic cancer.
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1 Introduction
Pancreatic cancer is the seventh leading cause of cancer death
in China and the fourth leading cause of cancer death in the
United States [1, 2]. In the United States alone more than a
quarter million people die from pancreatic cancer each year.
The prognosis of patients with pancreatic cancer is one of the
worst of all cancer types, due to the fact that little progress has
been made in its diagnosis and treatment during the past
decades [3, 4]. Therefore, it is of major relevance to seek for
novel methods to detect and treat patients with pancreatic
cancer.
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MicroRNAs (miRNAs) comprise a class of 19–23 nucleotides
long non-coding RNAs that can regulate endogenous gene ex-
pression by inducing the degradation or translational inhibition of
target mRNAs [5]. In recent years, miRNAs have been shown to
be able to modulate various biological processes, including em-
bryonic tissue development, neural differentiation and apoptosis
[6–8]. Importantly, a growing body of evidence indicates that
miRNA expression levels may directly be associated with cancer
development [6, 9–14]. In pancreatic cancer patients, several
miRNAs have been identified that are differentially expressed in
tumor tissues compared to adjacent normal tissues [15]. Among
them, microRNA-21 has been found to be up-regulated in
primary pancreatic cancers [16] and to modulate pancreatic can-
cer cell apoptosis [17]. ThismiRNAmay serve as a biomarker for
patients with pancreatic cancer [18]. Another example is
microRNA-34 that has been found to play an important role in
regulating the growth of pancreatic cancer stem cells [19].
Up- or down-regulation of miR-138 has been shown to
play an important role in regulating the growth and/or apopto-
sis of various cancers, including lung cancer [20], hepatocel-
lular carcinoma [21] and leukemia [22]. A recent study has
additionally shown that in the human pancreatic cancer cell
line PANC-1 up-regulation of miR-138may lead to a decrease
in focal adhesion kinase (FAK) expression [23]. As yet, how-
ever, it remains to be established whether miR-138 has a direct
role to play in pancreatic cancer.
Forkhead box C1 (FOXC1) is a member of the family of
forkhead box (FOX) transcription factors, originally identified as
being involved in Axenfeld-Rieger syndrome [24, 25]. In addi-
tion to its role in embryonic development, FOXC1 has also been
shown to serve as a biomarker for breast cancer [26, 27]. Other
studies have shown that up-regulation of FOXC1 may increase
cancer cell invasion and may imply a poor prognosis in cancer
patients [28, 29]. In case of pancreatic cancer, a high expression
level of FOXC1 has been found to be strongly associated with
the occurrence of ductal adenocarcinomas [30], but its exact role
in pancreatic cancer development is still largely unknown.
Here, we found that the expression levels of miR-138-5p, the
most common human isoform of miR-138, are significantly
down-regulated in both primary human pancreatic cancers and
human pancreatic cancer-derived cell lines. In addition, we found
that exogenous over-expression of miR-138-5p inhibits pancre-
atic cancer cell growth, both in vitro and in vivo, and that siRNA-
mediated silencing of FOXC1, a direct target of miR-138-5p,
similarly inhibits pancreatic cancer cell growth.
2 Materials and methods
2.1 Cell lines and cultures
The pancreatic cancer-derived cell lines AsPC-1, BxPc-3,
Capan-1, Capan-2, CFPAC-1, PANC-1, MIA PaCa-2 and
SW1990 were purchased from the American Type Culture
Collection and cultured in CS-C medium supplemented with
10 % fetal bovine serum. The human pancreas ductal epithe-
lial cell line HPDE was obtained from Dr. M.S. Tsao (Ontario
Cancer Institute, Ontario, Canada) and maintained as previ-
ously described [31]. Primary human normal pancreatic epi-
thelial cells were obtained from Cell System (Washington,
USA) and cultured in CS-C medium containing 10 % fetal
bovine serum (FBS) according to the manufacturer’s
instructions.
2.2 Primary tissue samples
Primary pancreatic tissue samples were obtained from 18
patients through a surgical protocol to resect a portion of the
pancreas in the Department of Hepatobiliary Surgery,
Affiliated Hospital of Guiyang Medical College, China,
from January 2013 to March 2014. This cohort included
10 male and 8 female patients. The mean age was
58.5 years (range: 34–67 years). Tumor stages were
determined using the ENETS [29] and AJCC-UICC
[30] pathological classification systems. All eighteen
patients exhibited a clear biopsy- or radiography-based
evidence of stage IV pancreatic carcinoma. Informed
consent forms were obtained from all patients. Autop-
sies were performed as soon as possible after death
(<8 h). Samples of primary pancreatic carcinomas, as
well as adjacent normal pancreatic tissues, were quickly
removed and a part of each sample was embedded in
OCT compound and stored at −80 °C. From the cancer
tissues, only those with a clear diagnosis of ductal
adenocarcinoma were included in this study. All proce-
dures used were reviewed and approved by the Ethics
Committees of the Affiliated Hospital of Guiyang Med-
ical College and the Affiliated Tongji Hospital.
2.3 Quantitative real-time reverse transcription-PCR
(qRT-PCR)
Total RNA and miRNA fractions were isolated from tissues
and cell lines using Trizol reagent according to manufacturer’s
protocol (Invitrogen, USA). Total RNA concentrations were
measured using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies) at 260 and 280 nm (A260/280),
and examined using an Agilent 2100 Bioanalyzer (Agilent
Technologies). Quantitative real-time reverse transcription-
PCR (qRT-PCR) assays were performed using a TaqMan
miRNA Assay according to manufacturer’s protocol (Applied
Biosystems). The amplification conditions were: 40 cycles of
15 s at 95 °C and 1 min at 60 °C. The expression levels of
miR-138-5p and FOXC1 were normalized by the expression
level of the housekeeping genes U6 and GAPDH,
respectively.
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2.4 Lentivirus production and transfection
Hsa-miR-138-5p oligonucleotide mimics and its non-specific
control were synthesized by Ribobio (RiboBio, Shanghai,
China). The respective coding sequences were then amplified
and cloned into pCDH-CMV-MCS-EF1-coGFP constructs
(System Biosciences, California, USA) to generate a miR-
138-5p mimics oligonucleotide vector (lv-miR-138-5p) and
its non-specific control vector (lv-control). Then, according to
manufacturer’s instructions, the lentiviral expression con-
structs and a pPACK packaging plasmid mix were co-
transfected into HEK-293 T cells, viral lv-miR-138-5p and
non-specific lv-control particles were collected and titers
were determined. In brief, the protocol for lentiviral
production was: (i) Day 1, for each plasmid to be
transfected 7×105 HEK-293 T cells were seeded in
5 mL medium in a 10 cm tissue culture dish at
37 °C, 5 % CO2 overnight, (ii) Day 2, the transfection
cocktails were added to the cells for 12–15 h, (iii) Day
3, the culture media were replaced by fresh media to
remove the transfection cocktails, (iv) Day 4, the culture
supernatants, containing lentiviral particles, were collect-
ed by centrifugation, transferred to polypropylene stor-
age tubes and stored at 4 °C . The lentiviral titers were
determined using a Lenti-X qPCRtitration kit according
to the manufacturer’s instructions (Clonetech, Mountain
View, CA, USA). Finally, pancreatic cells were
transfected with the lentiviruses using Lipofectamine
2000 (5 μl/ml) according to manufacturer’s protocol
(Invitrogen, Foster City, CA).
2.5 Cell proliferation and colony forming assays
Pancreatic cancer cells were transfected with either lv-miR-
138-5p or lv-control lentivirus and seeded in 6-well plates for
24 h. Viable cells were then transferred at a density of 2×104
cells per well to 24-well plates and cultured for another 72 h.
Cell proliferation was evaluated by measuring the fluores-
cence intensity of propidium iodide (PI) as described previ-
ously [32]. At 24, 48, 72 and 96 h the fluorescence intensities
were measured using a CytoFluor II multiwell plate reader
(PerSeptive Biosystems). For the colony formation assay, cells
were seeded in 6-well plates at a density of 1,000 cells per well
and cultured in an incubator. The cultures were terminated
when the clones were visible (~48 h), fixed in methanol, and
stained with hematoxylin for counting under a light micro-
scope. All experiments were performed in triplicate.
2.6 In vivo tumor formation
Capan-2 cells were transfected with lv-miR-138-5p mimic or
lv-control vectors for 24 h. Next, the cells were collected and
subcutaneously inoculated into female athymic NCr-nu/nu
nude mice (6-week old) using a 0.3 ml suspension containing
2×106 cells. The resulting tumor volumes were calculated
using the formula (length×width2)/2. All animal experiments
were performed according to the protocol approved by the
Animal Committees of the Affiliated Hospital of Guiyang
Medical College and the Affiliated Tongji Hospital.
2.7 Luciferase reporter assay
Routine PCR was performed on cDNA of Capan-2 cells to
amplify the wild-type 3’-UTR and mutant 3’-UTR (modified
miR-218 binding site, Fig. 5a) of FOXC1. Then, the wild-type
and mutant 3’-UTRs were inserted into a luciferase reporter
vector (pmiR-REPORT, Ambion, USA) to generate Luc-










































































Fig. 1 miR-138-5p expression levels in pancreatic cancer cell lines and
clinical samples. a miR-138-5p expression levels in cell lines relative to
HPDE and normal epithelia assessed by qRT-PCR (*, P<0.05). Data are
presented asMean ± SD and the experiments were performed in triplicate.
b miR-138-5p expression levels in 18 primary pancreatic cancer tissues
relative to 18 nonmalignant (normal) tissues assessed by qRT-PCR (*,
P<0.05). Data are presented as Mean ± SD and the experiments were
performed in triplicate
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constructs were verified by DNA sequencing. The pmiR-
REPORT control vector and the Luc-FOXC1 and Luc-
FOXC1-mu vectors were co-transfected with β-
galactosidase and Lv-miR-138-5p vectors into HEK-293 cells
in 12-well plates using Lipofectamine 2000 according to the
manufacturer’s protocol. Luciferase activities were examined
after 24 h using a luciferase reporter assay system (Promega,
USA) according to the manufacturer’s protocol. The signals
were normalized to theβ-galactosidase control vector activity.
The experiments were performed at least in triplicate.
2.8 Transfection of siRNA
A FOXC1-specific siRNA (si-FOXC1) and its non-specific
scramble siRNA (si-NC) were purchased from Stanta Cruz
(Santa Cruz Biotechnology, USA), and transfections were
carried out with Lipofectamine 2000 according to manufac-
turer’s recommended protocol. Briefly, Capan-2 and PANC-1
cells were transfected with either si-FOXC1 (100 nM) or si-
NC (100 nM) for 48 h, followed by examination of cell


























































Fig. 2 miR-138-5p inhibits
proliferation of pancreatic cancer
cells. Capan-2 and PANC-1 cells
were transfected with a lentiviral
vector expressing miR-138-5p
mimics (lv-miR-138-5p,
100 pmol) and its non-specific
control vector (lv-control,
100 pmol) for 48 h. a Endogenous
expression levels of miR-138-5p
after lentivirual transfection
measured by qRT-PCR
(*: P<0.05). b, c Effects of miR-
138-5p on cell proliferation of
pancreatic cancer cells assessed
by a cell proliferation assay at 24,
48, 72 and 96 h after seeding.
Pancreatic cancer cells without
lentiviral transfections were
included (blank control, BC). In
both Capan-2 (b) and PANC-1 (c)
cells proliferation was
significantly inhibited by lv-miR-
138-5p at 72 and 96 h compared
to lv-control (*: P<0.05)
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FOXC1 expression was examined by qRT-PCR 48 h after
transfection.
2.9 Western blotting
After culture, cell lysates were collected using routine proce-
dures and protein concentrations were determined using a
BCA kit (Thermo Scientific). Then 20 μg protein was run
on a 9 % SDS-PAGE gel at 70 V for 4 h, transferred to a
nitrocellulose membrane and incubated with a primary anti-
FOXC1 antibody (1:500, Santa Cruz Technology, Santa Cruz,
CA). A horseradish peroxidase-ECL method was used for X-
ray film exposure and measurement of FOXC1 protein ex-
pression levels. GAPDH was used as internal control.
2.10 Immunostaining
Formalin-fixed paraffin-embedded sections (5 μM) were pre-
pared from mouse xenografts. They were deparaffinized and
incubated with primary antibodies directed against FOXC1
and human Ki67. The respective proteins were visualized
using NexES automated stainers and the I-View Detection
Chemistry system (Ventana Medical Systems, Tucson, AZ).
2.11 Statistical analysis
In vivo tumor volumes were analyzed using one-way
ANOVA. Other data were presented as the mean±SD and
evaluated with a Student’s t-test. Statistical significance was
considered if P<0.05 in any analysis. All experiments were
performed at least three in triplicate.
3 Results
3.1 miR-138-5p is down-regulated in pancreatic cancer tissues
and cell lines
MiR-138-5p, one of the mature isoforms of the miR-138
family, has previously been shown to play a critical role in
many types of cancer [33–35]. Unlike miR-138-5p, the other
known mature isoform of the miR-138 family, miR-138-1-3p,
does not appear to exert any relevant biological functions in
humans (based on search results of Google Scholar and
PubMed). Therefore, we decided to focus in our study on
miR-138-5p.
First, we used qRT-PCR to assess the expression level of
miR-138-5p in 9 pancreatic cancer cell lines, a human pan-
creas ductal epithelial cell line (HPDE) and a primary culture
of normal pancreatic epithelial cells (Fig. 1a). By doing so, we
found that in all the pancreatic cancer cell lines tested the
expression level of miR-138-5p was significantly lower than
in the HPDE or primary normal pancreatic epithelial cells
(P<0.05). Next, we used qRT-PCR to assess the expression
level of miR-138-5p in 18 primary pancreatic cancer tissues
and 18matched normal pancreatic tissues (Fig. 1b). Again, we
found that the expression level of miR-138-5p in the pancre-
atic cancer tissues was significantly lower than that in the
adjacent non-cancer tissues (P<0.05).
3.2 Over-expression of miR-138-5p inhibits pancreatic cancer
cell proliferation in vitro
To better understand the functional role of miR-138-5p in
pancreatic cancer, we used a lentivirual miR-138-5p mimics
vector (lv-miR-138-5p) to exogenously up-regulate miR-138-
5p expression. For this, two pancreatic cancer cell lines were
used, Capan-2 and PANC-1. First, we verified the respective
Fig. 3 miR-138-5p over-expression inhibits Capan-2 tumor formation in
nude mice. Capan-2 cells were transfected with lv-miR-138-5p or lv-
control vectors for 24 h. Cells were collected and inoculated into female
athymic nude mice. a Images of the tumors 6 weeks after inoculation. b
Tumor volumes calculated using the formula: (length × width2)/2 from
week 1 to week 6 (*: P<0.05, one-way ANOVA). cRepresentative tissue
sections after immunostaining for Ki67 and FOXC1
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transfection efficiencies. The results obtained showed that
miR-138-5pwas significantly up-regulated in both transfected
cell lines (Fig. 2a, P<0.05). Next, we performed cell prolifer-
ation assays in both Capan-2 and PANC-1 cells. The results
showed that, after transfection with lv-miR-138-5p lentivirus,
the proliferation was significantly inhibited in both pancreatic
cancer cell lines 48 h to 96 h after transfection (Fig. 2b,
P<0.05).
3.3 Over-expression of miR-138-5p inhibits tumor formation
in vivo
We then set out to examine the effect of exogenous miR-138-
5p over-expression on pancreatic cancer growth in vivo. To
this end, Capan-2 cells were transfected with lv-miR-138-5p
or lv-control for 24 h. Next, the cells were collected and
subcutaneously inoculated into female athymic nude mice.
The results obtained showed that miR-138-5p over-
expression significantly inhibited Capan-2 tumor growth
in vivo (Fig. 3a-b, P<0.05). Subsequent immunostaining for
Ki-67 on tissue sections of mouse xenografts confirmed the
inhibitory effect of miR-138-5p over-expression on tumor cell
proliferation (Fig. 3c, top panel).
3.4 miR-138-5p modulates pancreatic cancer cells
through FOXC1
Finally, we set out to identify the molecular pathway (s)
underlying miR-138-5p action in pancreatic cancer cells. Very
recently, it was reported that FOXC1, a member of the family
of forkhead box (FOX) transcription factors, was highly
expressed in 85 patients with pancreatic ductal adenocarci-
nomas [30]. Through bioinformatic analyses, including
TargetScan, Pictar and miRANDA, we found that FOXC1
may serve as a direct target of miR-138-5p (Fig. 4a). Even
more interestingly, we found in the in vivo transplantation
experiment that the expression of FOXC1 in the grafted miR-
138-5p over-expressing tumor samples was significantly
hsa-miR-138-5p  3’...GCCGGACUAAGUGUUGUGGUCGA...5’
FOXC1 3’ UTR WT 5’...UGAGAGUAUUCACCACACCAGCG...3’















































































Fig. 4 miR-138-5p directly
targets FOXC1. a Predicted
binding site of miR-138-5p in 3’-
UTR of FOXC1. The mutated 3’-
UTR of FOXC1 (FOXC1-mu) is
also shown. b HEK 293 T cells
were transfected with pmiR-
REPORT control construct (Luc-




with β-galactosidase and lv-miR-
138-5p constructs. After 24 h,
cells were examined by luciferase
assay and the signals were
normalized to β-galactosidase
control vector activity in
triplicates. (*: P<0.05). After
qRT-PCR, expression levels of
FOXC1 were compared between
normal pancreatic cells and
pancreatic cancer cell lines c, as
well as primary pancreatic
cancers and normal clinical
patient samples d (*: P<0.05)
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down-regulated (Fig. 3c, bottom panel). Based on these ob-
servations, we hypothesized that FOXC1might be involved in
the miR-138 mediated regulation of pancreatic cancer cell
growth. To test this hypothesis, we used a luciferase assay
and, by doing so, confirmed that miR-138-5p indeed directly
targets FOXC1 (Fig. 4b). We also found by qRT-PCR that
FOXC1 is up-regulated in Capan-2 and PANC-1 cells
(Fig. 4c), as well as in primary pancreatic cancer tissues
(Fig. 4d), compared to normal pancreatic cells (HPDE) and
nonmalignant clinical tissues, respectively.
We then applied siRNA to knock down FOXC1 expression
in pancreatic cancer cells. To this end, 100 nMFOXC1 siRNA
(si-FOXC1) or non-specific control siRNA (si-NC) were ap-
plied to Capan-2 and PANC-1 pancreatic cancer cell cultures
for 24 h. The transfection efficiencies were checked by West-
ern blotting and showed that in both cell lines the FOXC1
protein expression levels were significantly reduced after
treatment with si-FOXC1 (Fig. 5a). We also found that the
effects of knocking down FOXC1 were similar to up-
regulating miR-138-5p, i.e., cell proliferation was significant-
ly inhibited in both Capan-2 and PANC-1 as assessed in a
colony-forming assay (Fig. 5b-c, P<0.05).
4 Discussion
Recently, large-scale genome, transcriptome and methylome
analyses of pancreatic cancers was used to map the mutational
landscape in more than 400 patients [36, 37]. In the present
study, we show for the first time that the epigenetic modifier
miR-138-5p is functionally involved in regulating pancreatic
cancer cell growth. We show that miR-138-5p is generally
under-expressed in pancreatic cancer cell lines and primary
patient samples and, subsequently, that exogenous miR-138-
5p over-expression can inhibit pancreatic cancer cell prolifer-
ation both in vitro and in vivo. These results are in line with
previous studies showing that miR-138-5p can inhibit the
growth of other cancer types and increase cancer cell
chemo-sensitivity [20–22]. Our results also suggest that the
molecular mechanism underlying miR-138-5p action in pan-
creatic cancer may be similar to its tumor suppressive role in
other types of cancer, since miR-138-5p is generally down-
regulated in pancreatic cancer tissues and since forced over-
expression of miR-138-5p inhibits pancreatic cancer cell
proliferation.
In the present study, we additionally show that FOXC1
may serve as a direct target of miR-138-5p in pancreatic
cancer. We found that the expression levels of FOXC1 were
significantly down-regulated by exogenous miR-138-5p over-
expression both in vitro and in vivo, and that subsequent
siRNA-mediated FOXC1 down-regulation yielded a similar
effect in reducing pancreatic cancer cell proliferation as did
over-expression of miR-138-5p. It has been shown by others
that FOXC1 acts as a complex regulator in breast cancer, as
both inhibiting and enhancing proliferative effects were ob-
served after FOXC1 up-regulation [27, 38, 39]. In pancreatic
cancer, it has been found that a high level of FOXC1 expres-
sion is strongly associated a with poor clinic outcome in
patients with ductal adenocarcinomas [30]. Thus, our finding
that FOXC1 is overall highly expressed in pancreatic cancer
cell lines and primary pancreatic cancer tissues, as well our
finding that FOXC1 down-regulation has an inhibitory (anti-
proliferative) effect on pancreatic cancer cell growth, supports
the idea that FOXC1 likely acts as a proliferative factor in
pancreatic cancer.
In conclusion, we identified a new regulatory microRNA,

























Fig. 5 Similar effects of FOXC1 knock down and miR-138-5p over-
expression on pancreatic cancer cells. a Capan-2 and PANC-1 cells were
transfected with FOXC1 siRNA (si-FOXC1, 100 nM) or non-specific
control siRNA (si-NC, 100 nM). The endogenous expression levels of
FOXC1 were measured by qRT-PCR 24 h after transfection. b Colony
formation assay performed on both Capan-2 and PANC-1 cells 48 h after
transfection. c Colony numbers per dish compared between si-NC treat-
ment and si-FOXC1 treatment (*, ***: P<0.05)
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mechanism by which miR-138-5p acts to regulate pancreatic
cancer cell proliferation. Up-regulation of the tumor suppres-
sor miR-138-5p may serve as a new therapeutic option for
patients with pancreatic cancer.
Acknowledgments This work was supported by the National Natural
Science Foundation of China (No. 81160311), the International Science
&Technology Cooperation Program of China (NO.2014DFA31420) and
the Outstanding Young Training Project of Science and Education of
Guizhou Province, China. NO. [2012] 177.
Conflict of interest The authors declare no conflict of interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. A. Jemal, R. Siegel, J. Xu, E. Ward, Cancer statistics, 2010. CA
Cancer J Clin 60, 277–300 (2010)
2. W. Chen, R. Zheng, S. Zhang, P. Zhao, G. Li, L.Wu, J. He, Report of
incidence and mortality in China cancer registries, 2009. Chin J
Cancer Res Chung-kuo yen cheng yen chiu. 25, 10–21 (2013)
3. K. Hirata, S. Egawa, Y. Kimura, T. Nobuoka, H. Oshima, T.
Katsuramaki, T. Mizuguchi, T. Furuhata, Current status of surgery
for pancreatic cancer. Dig. Surg. 24, 137–147 (2007)
4. S. Gillen, T. Schuster, C. Meyer Zum Buschenfelde, H. Friess, J.
Kleeff, Preoperative/neoadjuvant therapy in pancreatic cancer: a
systematic review and meta-analysis of response and resection per-
centages. PLoS Med. 7, e1000267 (2010)
5. R.S. Pillai, MicroRNA function: multiple mechanisms for a tiny
RNA? RNA 11, 1753–1761 (2005)
6. G.A. Calin, C.M. Croce, MicroRNA signatures in human cancers.
Nat. Rev. Cancer 6, 857–866 (2006)
7. W. Feng, Y. Feng, MicroRNAs in neural cell development and brain
diseases. Sci. China Life Sci. 54, 1103–1112 (2011)
8. S. Bian, T. Sun, Functions of noncoding RNAs in neural develop-
ment and neurological diseases. Mol. Neurobiol. 44, 359–373 (2011)
9. T. Papagiannakopoulos, K.S. Kosik, MicroRNAs: regulators of on-
cogenesis and stemness. BMC Med. 6, 15 (2008)
10. Blandino G, Fazi F, Donzelli S, Kedmi M, Sas-Chen A, Muti P,
Strano S and Yarden Y. Tumor suppressor microRNAs: A novel non-
coding alliance against cancer. FEBS letters 2014
11. J.K. Palanichamy, D.S. Rao, miRNA dysregulation in cancer: to-
wards a mechanistic understanding. Front. Genet. 5, 54 (2014)
12. R. Nagadia, P. Pandit, W.B. Coman, J. Cooper-White, C. Punyadeera,
miRNAs in head and neck cancer revisited. Cell Oncol. Dordr. 36, 1–
7 (2013)
13. Y. Wang, M. Li, W. Zang, Y. Ma, N. Wang, P. Li, T. Wang, G. Zhao,
MiR-429 up-regulation induces apoptosis and suppresses invasion by
targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell Oncol. Dordr
36, 385–394 (2013)
14. L. Rask, E. Balslev, R. Sokilde, E. Hogdall, H. Flyger, J. Eriksen, T.
Litman, Differential expression of miR-139, miR-486 and miR-21 in
breast cancer patients sub-classified according to lymph node status.
Cell Oncol. Dordr 37, 215–227 (2014)
15. E.J. Lee, Y. Gusev, J. Jiang, G.J. Nuovo, M.R. Lerner, W.L. Frankel,
D.L. Morgan, R.G. Postier, D.J. Brackett, T.D. Schmittgen,
Expression profiling identifies microRNA signature in pancreatic
cancer. Int. J. Cancer 120, 1046–1054 (2007)
16. M. Dillhoff, J. Liu, W. Frankel, C. Croce, M. Bloomston,
MicroRNA-21 is overexpressed in pancreatic cancer and a potential
predictor of survival. J. Gastrointest. Surg. 12, 2171–2176 (2008)
17. T. Moriyama, K. Ohuchida, K. Mizumoto, J. Yu, N. Sato, T. Nabae,
S. Takahata, H. Toma, E. Nagai, M. Tanaka, MicroRNA-21 modu-
lates biological functions of pancreatic cancer cells including their
proliferation, invasion, and chemoresistance. Mol. Cancer Ther. 8,
1067–1074 (2009)
18. W. Zhu, B. Xu, MicroRNA-21 Identified as predictor of cancer
outcome: a meta-analysis. PLoS One 9, e103373 (2014)
19. Q. Ji, X. Hao, M. Zhang, W. Tang, M. Yang, L. Li, D. Xiang, J.T.
Desano, G.T. Bommer, D. Fan, E.R. Fearon, T.S. Lawrence, L. Xu,
MicroRNA miR-34 inhibits human pancreatic cancer tumor-
initiating cells. PLoS One 4, e6816 (2009)
20. Y. Gao, X. Fan,W. Li,W. Ping, Y. Deng, X. Fu, miR-138-5p reverses
Gefitinib resistance in non-small cell lung cancer cells via negatively
regulating G protein-coupled receptor 124. Biochem. Biophys. Res.
Commun. 446, 179–186 (2014)
21. W.Wang, L.J. Zhao, Y.X. Tan, H. Ren, Z.T. Qi, MiR-138 induces cell
cycle arrest by targeting cyclin D3 in hepatocellular carcinoma.
Carcinogenesis 33, 1113–1120 (2012)
22. X. Zhao, L. Yang, J. Hu, J. Ruan, miR-138 might reverse
multidrug resistance of leukemia cells. Leuk. Res. 34, 1078–
1082 (2010)
23. V.M. Golubovskaya, B. Sumbler, B. Ho, M. Yemma, W.G. Cance,
MiR-138 and MiR-135 directly target focal adhesion kinase, inhibit
cell invasion, and increase sensitivity to chemotherapy in cancer
cells. Anticancer. Agents Med. Chem. 14, 18–28 (2014)
24. T. Kume, K.Y. Deng, V. Winfrey, D.B. Gould, M.A. Walter, B.L.
Hogan, The forkhead/winged helix gene Mf1 is disrupted in the
pleiotropic mouse mutation congenital hydrocephalus. Cell 93,
985–996 (1998)
25. A.J. Mears, T. Jordan, F. Mirzayans, S. Dubois, T. Kume, M. Parlee,
R. Ritch, B. Koop,W.L. Kuo, C. Collins, J.Marshall, D.B. Gould,W.
Pearce, P. Carlsson, S. Enerback, J. Morissette, S. Bhattacharya, B.
Hogan, V. Raymond, M.A. Walter, Mutations of the forkhead/
winged-helix gene, FKHL7, in patients with Axenfeld-Rieger anom-
aly. Am. J. Hum. Genet. 63, 1316–1328 (1998)
26. P.S. Ray, S.P. Bagaria, J. Wang, J.M. Shamonki, X. Ye, M.S. Sim, S.
Steen, Y. Qu, X. Cui, A.E. Giuliano, Basal-like breast cancer defined
by FOXC1 expression offers superior prognostic value: a retrospec-
tive immunohistochemical study. Ann. Surg. Oncol. 18, 3839–3847
(2011)
27. P.S. Ray, J.Wang, Y. Qu,M.S. Sim, J. Shamonki, S.P. Bagaria, X. Ye,
B. Liu, D. Elashoff, D.S. Hoon, M.A. Walter, J.W. Martens, A.L.
Richardson, A.E. Giuliano, X. Cui, FOXC1 is a potential prognostic
biomarker with functional significance in basal-like breast cancer.
Cancer Res. 70, 3870–3876 (2010)
28. J. Wang, P.S. Ray, M.S. Sim, X.Z. Zhou, K.P. Lu, A.V. Lee, X. Lin,
S.P. Bagaria, A.E. Giuliano, X. Cui, FOXC1 regulates the functions
of human basal-like breast cancer cells by activating NF-kappaB
signaling. Oncogene 31, 4798–4802 (2012)
29. Y. Xu, Q.S. Shao, H.B. Yao, Y. Jin, Y.Y. Ma, L.H. Jia,
Overexpression of FOXC1 correlates with poor prognosis in gastric
cancer patients. Histopathology 64, 963–970 (2014)
30. L. Wang, F. Gu, C.Y. Liu, R.J. Wang, J. Li, J.Y. Xu, High level of
FOXC1 expression is associated with poor prognosis in pancreatic
ductal adenocarcinoma. Tumour Biol. J. Int. Soc. Oncol. Dev. Biol.
Med. 34, 853–858 (2013)
31. N. Radulovich, J.Y. Qian, M.S. Tsao, Human pancreatic duct epithe-
lial cell model for KRAS transformation. Methods Enzymol. 439, 1–
13 (2008)
32. L. Zhang, K. Mizumoto, N. Sato, T. Ogawa, M. Kusumoto, H.
Niiyama, M. Tanaka, Quantitative determination of apoptotic death
in cultured human pancreatic cancer cells by propidium iodide and
digitonin. Cancer Lett. 142, 129–137 (1999)
180 C. Yu et al.
33. Y. Gao, X. Fan,W. Li,W. Ping, Y. Deng, X. Fu, miR-138-5p reverses
gefitinib resistance in non-small cell lung cancer cells via negatively
regulating G protein-coupled receptor 124. Biochem. Biophys. Res.
Commun. 446, 179–186 (2014)
34. Ayaz L, Cayan F, Balci S, Gorur A, Akbayir S, Yildirim Yaroglu H,
Dogruer Unal N and Tamer L. Circulating microRNA expression
profiles in ovarian cancer. J Obstet Gynaecol 2014; 1–5
35. C. Augello, U. Gianelli, F. Savi, A. Moro, E. Bonoldi, M.
Gambacorta, V. Vaira, L. Baldini, S. Bosari, MicroRNA as potential
biomarker in HCV-associated diffuse large B-cell lymphoma. J. Clin.
Pathol. 67, 697–701 (2014)
36. A.V. Biankin, N. Waddell, K.S. Kassahn, M.C. Gingras, L.B.
Muthuswamy, A.L. Johns, D.K. Miller, P.J. Wilson, A.M. Patch, J.
Wu, D.K. Chang, M.J. Cowley, B.B. Gardiner, S. Song, I.
Harliwong, S. Idrisoglu, C. Nourse, E. Nourbakhsh, S. Manning, S.
Wani, M. Gongora, M. Pajic, C.J. Scarlett, A.J. Gill, A.V. Pinho, I.
Rooman, M. Anderson, O. Holmes, C. Leonard, D. Taylor, S. Wood,
Q. Xu, K. Nones, J.L. Fink, A. Christ, T. Bruxner, N. Cloonan, G.
Kolle, F. Newell, M. Pinese, R.S. Mead, J.L. Humphris, W. Kaplan,
M.D. Jones, E.K. Colvin, A.M. Nagrial, E.S. Humphrey, A. Chou,
V.T. Chin, L.A. Chantrill, A. Mawson, J.S. Samra, J.G. Kench, J.A.
Lovell, R.J. Daly, N.D. Merrett, C. Toon, K. Epari, N.Q. Nguyen, A.
Barbour, N. Zeps, I. Australian Pancreatic Cancer Genome, N.
Kakkar, F. Zhao, Y.Q. Wu, M. Wang, D.M. Muzny, W.E. Fisher,
F.C. Brunicardi, S.E. Hodges, J.G. Reid, J. Drummond, K. Chang, Y.
Han, L.R. Lewis, H. Dinh, C.J. Buhay, T. Beck, L. Timms, M. Sam,
K. Begley, A. Brown, D. Pai, A. Panchal, N. Buchner, R. De Borja,
R.E. Denroche, C.K. Yung, S. Serra, N. Onetto, D. Mukhopadhyay,
M.S. Tsao, P.A. Shaw, G.M. Petersen, S. Gallinger, R.H. Hruban, A.
Maitra, C.A. Iacobuzio-Donahue, R.D. Schulick, C.L. Wolfgang,
R.A. Morgan, R.T. Lawlor, P. Capelli, V. Corbo, M. Scardoni, G.
Tortora, M.A. Tempero, K.M. Mann, N.A. Jenkins, P.A. Perez-
Mancera, D.J. Adams, D.A. Largaespada, L.F. Wessels, A.G. Rust,
L.D. Stein, D.A. Tuveson, N.G. Copeland, E.A. Musgrove, A.
Scarpa, J.R. Eshleman, T.J. Hudson, R.L. Sutherland, D.A.
Wheeler, J.V. Pearson, J.D. McPherson, R.A. Gibbs, S.M.
Grimmond, Pancreatic cancer genomes reveal aberrations in axon
guidance pathway genes. Nature 491, 399–405 (2012)
37. A. Geurts van Kessel, The cancer genome: from structure to function.
Cell Oncol. Dordr 37, 155–165 (2014)
38. J. Du, L. Li, Z. Ou, C. Kong, Y. Zhang, Z. Dong, S. Zhu, H. Jiang, Z.
Shao, B. Huang, J. Lu, FOXC1, a target of polycomb, inhibits
metastasis of breast cancer cells. Breast Cancer Res. Treat. 131, 65–
73 (2012)
39. T.K. Chung, T.S. Lau, T.H. Cheung, S.F. Yim, K.W. Lo, N.S. Siu,
L.K. Chan, M.Y. Yu, J. Kwong, G. Doran, L.M. Barroilhet, A.S. Ng,
R.R. Wong, V.W. Wang, S.C. Mok, D.I. Smith, R.S. Berkowitz, Y.F.
Wong, Dysregulation of microRNA-204 mediates migration and
invasion of endometrial cancer by regulating FOXC1. Int. J. Cancer
J. Int. Cancer 130, 1036–1045 (2012)
miR-138-5p regulates pancreatic cancer 181
